Estrella Lopez-Gordo obtained a BSc in Biotechnology at the Universitat Autònoma de Barcelona (UAB) and completed an MSc in Biomedical Research at the Universitat Pompeu Fabra (UPF) in Spain. As she developed her interest in adenoviral vectors, she moved to the University of Glasgow in the UK for her
PhD in Virology. She then moved to the USA, where she worked as a postdoctoral fellow at the Icahn School of Medicine in New York City, focusing on the development of novel adeno-associated virus (AAV) vectors for targeted gene therapy and, as a Scientist II at Capsida Biotherapeutics, engineering AAV vectors for CNS-targeted gene therapy. Currently, she is working as a Senior Scientist at Affinia Therapeutics, continuing her contributions in the gene therapy field by engineering AAV vectors for targeted delivery.
please check intended meaning retained
Thomas Weber is the Senior Director of Viral Platforms at Spark Therapeutics, Inc. He used to work as an Assistant Professor (1999–2015) and Associate Professor (2016–2021) at the Icahn School of Medicine in Mount Sinai. He received an M.Sc. in Biochemistry and a Dr. sc. nat (Ph.D.) in Biochemistry and Organic Chemistry from the Swiss Federal Institute of Technology, in 1990 and 1994, respectively, and was a postdoctoral fellow in Dr. James E. Rothman’s laboratory until 1999. The focus of the research of his team at Spark Therapeutics is to develop AAV vectors with improved potency, the ability to efficiently transduce specific cell types, and displaying increased resistance to pre-existing anti-AAV antibodies.
